术前使用西妥昔单抗后的组织学及术后即时结果：病例匹配对照研究 - Suppr

Suppr

超能文献

Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study.

作者信息

Spiliotis John, Zoras Odysseas

出版信息

World J Surg. 2011 May;35(5):1153-4. doi: 10.1007/s00268-010-0915-4.

DOI:10.1007/s00268-010-0915-4

PMID:21184075

Abstract

摘要

相似文献

Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study.术前使用西妥昔单抗后的组织学及术后即时结果：病例匹配对照研究

World J Surg. 2011 May;35(5):1153-4. doi: 10.1007/s00268-010-0915-4.

Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases.术前靶向治疗对结直肠肝转移切除术后并发症的影响。

Int J Colorectal Dis. 2012 May;27(5):635-45. doi: 10.1007/s00384-011-1360-z. Epub 2011 Dec 6.

Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study.术前使用西妥昔单抗后的组织学及术后即刻结果：病例匹配对照研究

World J Surg. 2010 Nov;34(11):2765-72. doi: 10.1007/s00268-010-0731-x.

Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.接受新辅助化疗（包括使用贝伐单抗或西妥昔单抗）的结直肠癌肝转移患者在肝切除术后的组织学反应、肿瘤破坏模式及临床结局。

Eur J Surg Oncol. 2015 Jul;41(7):868-74. doi: 10.1016/j.ejso.2015.03.223. Epub 2015 Mar 24.

Cetuximab in metastatic colorectal cancer.西妥昔单抗用于转移性结直肠癌

Lancet Oncol. 2010 Apr;11(4):313-4; author reply 314. doi: 10.1016/S1470-2045(10)70019-X.

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.西妥昔单抗新辅助化疗后结直肠癌肝转移的肿瘤反应和二次可切除性：CELIM 随机 2 期试验。

Lancet Oncol. 2010 Jan;11(1):38-47. doi: 10.1016/S1470-2045(09)70330-4. Epub 2009 Nov 26.

Improved first-line chemotherapy: a better chance for surgery?一线化疗的改进：手术机会是否增加？

Lancet Oncol. 2010 Jan;11(1):4-5. doi: 10.1016/S1470-2045(09)70345-6. Epub 2009 Nov 26.

Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.靶向分子治疗（西妥昔单抗和贝伐单抗）不会引起额外的肝毒性：一项病例对照研究的初步结果。

Eur J Surg Oncol. 2010 Jun;36(6):575-82. doi: 10.1016/j.ejso.2010.04.010. Epub 2010 May 7.

Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.术前化疗对结直肠癌肝转移患者行大肝切除术风险的影响。

Ann Surg. 2006 Nov;244(5):833-5; author reply 835. doi: 10.1097/01.sla.0000243600.98464.a5.

Consequences of chemotherapy on resection of colorectal liver metastases.化疗对结直肠肝转移切除术的影响。

J Visc Surg. 2010 Aug;147(4):e193-201. doi: 10.1016/j.jviscsurg.2010.06.004. Epub 2010 Jul 23.

本文引用的文献

Next-generation sequencing and epigenome technologies: potential medical applications.下一代测序与表观基因组技术：潜在的医学应用。

Expert Rev Med Devices. 2010 Nov;7(6):723-6. doi: 10.1586/erd.10.68.

Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.结直肠癌：西妥昔单抗、KRAS、BRAF、PIK3CA突变及其他相关研究

Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):525-9. doi: 10.1586/egh.10.62.

Complete genome sequencing and network modeling to overcome trastuzumab resistance.全基因组测序和网络建模以克服曲妥珠单抗耐药性。

Pharmacogenomics. 2010 Aug;11(8):1039-43. doi: 10.2217/pgs.10.104.

Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice.基于下一代基因组测序的生物标志物：医疗实践中的问题与挑战

Biomark Med. 2010 Aug;4(4):583-6. doi: 10.2217/bmm.10.70.

Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study.术前使用西妥昔单抗后的组织学及术后即刻结果：病例匹配对照研究

World J Surg. 2010 Nov;34(11):2765-72. doi: 10.1007/s00268-010-0731-x.

Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment.基因型-表型图谱与分子网络：克服结直肠癌对靶向治疗耐药性的一种有前景的解决方案。

Expert Rev Mol Diagn. 2010 Jul;10(5):541-5. doi: 10.1586/erm.10.49.

Systems medicine: a real approach for future personalized oncology?系统医学：未来个性化肿瘤学的切实途径？

Pharmacogenomics. 2010 Mar;11(3):283-7. doi: 10.2217/pgs.10.36.

From tumor size and HER2 status to systems oncology for very early breast cancer treatment.从肿瘤大小和HER2状态到用于极早期乳腺癌治疗的系统肿瘤学。

Expert Rev Anticancer Ther. 2010 Feb;10(2):123-8. doi: 10.1586/era.09.177.

Isolated tumor cells in breast cancer.乳腺癌中的孤立肿瘤细胞。

N Engl J Med. 2009 Nov 12;361(20):1994-5; author reply 1995-6.

Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.当前癌症个体化抗血管生成治疗的关注点与挑战。

Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验